Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Posterior Uveitis Overview 6
Therapeutics Development 7
Pipeline Products for Posterior Uveitis - Overview 7
Posterior Uveitis - Therapeutics under Development by Companies 8
Posterior Uveitis - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Posterior Uveitis - Products under Development by Companies 12
Posterior Uveitis - Companies Involved in Therapeutics Development 13
Aciont Inc. 13
Neuroptis Biotech 14
Oculis ehf 15
pSivida Corp. 16
Regeneron Pharmaceuticals Inc 17
Sandoz International GmbH 18
Santen Pharmaceutical Co., Ltd. 19
Posterior Uveitis - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
adalimumab biosimilar - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
dexamethasone acetate - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
dexamethasone sodium phosphate - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
EYS-606 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
fluocinolone acetonide SR - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
NOP-3 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
sarilumab - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
sirolimus - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Posterior Uveitis - Dormant Projects 52
Posterior Uveitis - Discontinued Products 53
Posterior Uveitis - Product Development Milestones 54
Featured News & Press Releases 54
Oct 04, 2016: Phase 3 trial of Medidur in Posterior Segment Uveitis Meets Enrollment Target 54
Aug 15, 2016: Topline Results from First Phase 3 Trial of pSividas Medidur Presented at ASRS Annual Meeting 54
Aug 09, 2016: Primary Endpoint Met in pSivida’s Utilization Study of New Medidur Inserter with Smaller Diameter Needle 55
Jul 27, 2016: pSivida’s Medidur Maintains Same High Statistical Significance in Primary Endpoint through 12 Months in First Phase 3 Trial (p Less Than 0.00000001) 55
Jul 14, 2016: Investigator-Sponsored Phase 2 Study Results Show pSivida’s Medidur Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve 56
May 02, 2016: pSividas Medidur for Posterior Uveitis Granted Orphan Drug Designation in Europe 57
Mar 15, 2016: Additional Favorable Six-Month Safety Results for pSividas Medidur for Posterior Uveitis 58
Dec 28, 2015: pSivida Plans Medidur EU Marketing Approval Application Based on Single Phase 3 Clinical Trial 58
Dec 22, 2015: pSivida Medidur Meets Primary Efficacy Endpoint in Phase 3 Trial: High Statistical Significance in Prevention of Recurrence of Posterior Uveitis 59
Sep 28, 2015: pSivida Announces NDA for Medidur Now Planned Using Six-Month Efficacy Data from Both Phase III Trials; FDA Concurs 61
May 19, 2015: pSivida Reports Positive IOP Safety Data in Phase III Trial of Medidur for Posterior Uveitis 61
Mar 26, 2015: pSivida Completes Targeted Enrollment of Phase III Trial of Medidur for Posterior Uveitis 62
Apr 15, 2013: Aciont To Present at ARVO 2013 Annual Meeting 63
Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 64
Disclaimer 65

List of Tables
Number of Products under Development for Posterior Uveitis, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Late Stage Development, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 10
Comparative Analysis by Early Stage Development, H2 2016 11
Products under Development by Companies, H2 2016 12
Posterior Uveitis - Pipeline by Aciont Inc., H2 2016 13
Posterior Uveitis - Pipeline by Neuroptis Biotech, H2 2016 14
Posterior Uveitis - Pipeline by Oculis ehf, H2 2016 15
Posterior Uveitis - Pipeline by pSivida Corp., H2 2016 16
Posterior Uveitis - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 17
Posterior Uveitis - Pipeline by Sandoz International GmbH, H2 2016 18
Posterior Uveitis - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016 19
Assessment by Monotherapy Products, H2 2016 20
Number of Products by Stage and Target, H2 2016 22
Number of Products by Stage and Mechanism of Action, H2 2016 24
Number of Products by Stage and Route of Administration, H2 2016 26
Number of Products by Stage and Molecule Type, H2 2016 28
Posterior Uveitis - Dormant Projects, H2 2016 52
Posterior Uveitis - Discontinued Products, H2 2016 53

List of Figures
Number of Products under Development for Posterior Uveitis, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Late Stage Development, H2 2016 9
Assessment by Monotherapy Products, H2 2016 20
Number of Products by Targets, H2 2016 21
Number of Products by Stage and Targets, H2 2016 21
Number of Products by Mechanism of Actions, H2 2016 23
Number of Products by Stage and Mechanism of Actions, H2 2016 23
Number of Products by Routes of Administration, H2 2016 25
Number of Products by Stage and Routes of Administration, H2 2016 25
Number of Products by Molecule Types, H2 2016 27
Number of Products by Stage and Molecule Types, H2 2016 27